Patients who are unable to reliably tolerate and/or receive oral medicationsXx_NEWLINE_xXInability to take oral medications on a continuous basisXx_NEWLINE_xXParticipants must be able to take oral medicationsXx_NEWLINE_xXInability to swallow oral medicationsXx_NEWLINE_xXAble to swallow and retain oral medication (note: for patients unable to swallow tablets, an oral suspension preparation is acceptable)Xx_NEWLINE_xXPatients must have the ability to swallow oral medicationXx_NEWLINE_xXAbility to swallow liquidsXx_NEWLINE_xXPatients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow, retain, and/or absorb the drug are excludedXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXAble to swallow and retain oral medicationXx_NEWLINE_xXAbility to swallow oral medicationsXx_NEWLINE_xXSubjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel* Active peptic ulcer disease* Malabsorption syndromeXx_NEWLINE_xXPatients must be able to swallow oral medicationsXx_NEWLINE_xXPatients must be able to swallow medication by oral routeXx_NEWLINE_xXAbility to take oral medicationsXx_NEWLINE_xXAbility to swallow oral medicationsXx_NEWLINE_xXAbility to swallow medicationXx_NEWLINE_xXAbility to swallow oral medicationsXx_NEWLINE_xXPatients must be able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparibXx_NEWLINE_xXAble to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparibXx_NEWLINE_xXPatients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparibXx_NEWLINE_xXPatients must have the ability to swallow oral dosage formsXx_NEWLINE_xXPatients must be able to take oral medications (i.e., swallow pills whole); patients must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures that could in the opinion of the treating investigator affect absorption, or active peptic ulcer disease; patients with intractable nausea or vomiting are not eligibleXx_NEWLINE_xXAbility to swallow oral medicationsXx_NEWLINE_xXAble to take oral medication and has no history of gastric surgery or pathologyXx_NEWLINE_xXPatient is unable to swallow or keep down oral medicationXx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Patients must be able to swallow oral medications and must not have a gastro-intestinal disorder with diarrhea as a major symptom or that may alter absorption such as malabsorption syndromes or gastric resectionXx_NEWLINE_xXAbility to swallow and retain oral medicationXx_NEWLINE_xXPatients must have the ability to swallow and retain oral medicationXx_NEWLINE_xXPatients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excludedXx_NEWLINE_xXSubject is able to swallow and retain oral medication and does not have uncontrolled emesis or gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXPatients must be able to swallow oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparibXx_NEWLINE_xXAbility to swallow and retain oral medicationXx_NEWLINE_xXPatients that unable to swallow oral medications are ineligibleXx_NEWLINE_xX